Complete Wegovy Dose Journey - BMI Assessment To Maintenance
BMI For Wegovy: Complete Dose Range Availability
The BMI requirements for Wegovy remain consistent across all dose strengths, but finding a pharmacy that stocks every dose from 0.25mg through 2.4mg can prove challenging. EverydayMeds maintains complete inventory of all five Wegovy doses, eliminating the common problem of patients needing to switch pharmacies mid-treatment when their current provider cannot supply their next dose escalation. This comprehensive approach to BMI for Wegovy treatment ensures continuity of care from your initial starter dose through long-term maintenance therapy.
Your BMI calculation determines Wegovy eligibility regardless of which dose strength you require during treatment progression. Licensed for adults with BMI ≥30kg/m², or BMI ≥27kg/m² with weight-related comorbidities such as type 2 diabetes or hypertension, this prescription-only medicine follows a mandatory dose escalation schedule. Having all doses readily available means your BMI for Wegovy journey continues smoothly without treatment interruptions caused by supply chain limitations at other pharmacies.
Wegovy Pricing Across All BMI-Eligible Dose Strengths
Understanding the complete cost structure for BMI-eligible Wegovy treatment helps patients budget for their entire weight management journey. Our starter 0.25mg dose costs £79.99 (weeks 1-4), progressing to 0.5mg at £94.99 (weeks 5-8), then 1mg at £99.99 (weeks 9-12), followed by 1.7mg at £139.99 (weeks 13-16), reaching maintenance 2.4mg at £209.99 from week 17 onwards. New customers apply code FIRST40 at checkout, while returning customers use code DOSE25 to access these competitive prices.
Our bundle options provide convenient multi-dose packages for patients meeting BMI criteria for Wegovy treatment. The Intro Trio Bundle (0.25mg, 0.5mg, 1mg) costs £299.99, covering your first 12 weeks of dose escalation in a single order. For patients reaching maintenance phase, the Ultimate Stability Trio provides three months of 2.4mg supply for £649.99, ensuring consistent availability of your prescribed dose strength without monthly reordering concerns.
Clinical Evidence Supporting BMI Thresholds For Wegovy
The STEP clinical trial programme established the BMI criteria for Wegovy prescription across all dose strengths currently available. In STEP 1, patients taking Wegovy alongside a reduced-calorie diet and increased physical activity achieved approximately 15% average weight loss at 68 weeks compared to 2.4% with placebo (Wilding et al., NEJM, 2021). These results supported MHRA licensing for the specific BMI thresholds used in UK clinical practice.
Long-term sustainability data from STEP 5 demonstrated that patients meeting BMI requirements for Wegovy maintained approximately clinically studied weight loss at two years when continuing treatment. The SELECT cardiovascular outcomes trial showed a 20% reduction in major cardiovascular events (HR 0.80) in patients with established cardiovascular disease, supporting the clinical rationale for BMI-based prescribing criteria.
How Wegovy Works Regardless Of Your Qualifying BMI Level
Wegovy contains semaglutide, a GLP-1 receptor agonist that mimics a natural fullness hormone regardless of whether you qualify through BMI ≥30 or BMI ≥27 with comorbidities. This mechanism reduces appetite and promotes feelings of satiety after smaller meals, helping patients adhere to the reduced-calorie diet component of their weight management plan. The medication works on brain appetite centres, potentially reducing food cravings and making portion control more manageable. Unlike rapid-acting appetite suppressants, Wegovy provides sustained appetite regulation throughout the week with once-weekly dosing. All dose strengths from 0.25mg to 2.4mg work through this same mechanism, with higher doses providing enhanced appetite suppression as treatment progresses.
Streamlined Ordering Process For All BMI-Eligible Patients
Our 3-minute online clinical assessment determines your BMI eligibility for Wegovy and identifies the appropriate starting dose for your treatment journey. Questions cover your height, weight, medical history, current medications, and weight-related health conditions to calculate BMI and assess comorbidity criteria. Once submitted, our prescribers review your assessment within 3 working days (or 24 hours with express service), confirming both your BMI qualification and prescribed dose strength. Upon approval, your Wegovy dose dispatches via next-day delivery using cold-chain temperature-controlled packaging to maintain medication stability. This streamlined process applies to all dose strengths, ensuring quick access whether you're starting 0.25mg or progressing to higher doses.
Storage Requirements And Practical Considerations Across All Wegovy Doses
All Wegovy dose strengths require identical storage conditions regardless of your qualifying BMI level or prescribed dose. Store unused pens in the fridge at 2-8°C until first use, with the flexibility to keep pens at room temperature below 30°C for up to 6 weeks once removed from refrigeration. Each FlexTouch pen contains four weekly doses of your prescribed strength, requiring weekly injections on the same day each week. The mandatory dose escalation schedule progresses every four weeks: 0.25mg for weeks 1-4, 0.5mg for weeks 5-8, 1mg for weeks 9-12, 1.7mg for weeks 13-16, then 2.4mg maintenance from week 17 onwards. This progression cannot be accelerated regardless of your BMI level or initial weight loss response, ensuring optimal tolerability as your body adjusts to increasing semaglutide levels.
BMI Assessment And Comprehensive Dose Planning Strategy
Meeting BMI requirements for Wegovy represents just the beginning of a long-term weight management commitment requiring strategic dose planning. Many patients underestimate the importance of pharmacy continuity when calculating their total treatment investment across all five dose strengths. EverydayMeds' complete inventory eliminates the disruption of switching providers when your local pharmacy cannot source your next prescribed dose.
Our clinical team, registered with GPhC #9012878, understands that BMI qualification for Wegovy indicates a serious commitment to sustained lifestyle changes alongside medication therapy. By maintaining stock of every dose strength, we support your entire treatment journey from initial BMI assessment through long-term maintenance, ensuring treatment continuity that many single-dose suppliers cannot ensure.
Securing Your Complete BMI-Qualified Wegovy Treatment Journey
Ready to begin your BMI-qualified Wegovy journey with assured access to all dose strengths? Our comprehensive stock levels mean you'll never face treatment interruption due to supply shortages affecting your prescribed dose escalation schedule. Complete your clinical assessment today using code FIRST40 for new patients or DOSE25 for returning customers to access our competitive pricing across all Wegovy strengths. With next-day cold-chain delivery and expert clinical support from our GPhC-registered team, EverydayMeds provides the stability and continuity your weight management journey deserves. Visit our Wegovy collection at https://everydaymeds.co.uk/collections/wegovy to begin your comprehensive treatment pathway today. Remember, this prescription-only medicine works best alongside your commitment to a reduced-calorie diet and increased physical activity, supported by our complete dose range availability.
Reviewed by the EverydayMeds Clinical Team · GPhC #9012878 · Last updated February 2026
